DR. DONALD WILLIAM KUFE, M.D.
Osteopathic Medicine at Brookline Ave, Boston, MA
License number
Massachusetts 41308
Category
Osteopathic Medicine
Type
Hematology & Oncology
Address
Address
2
450 Brookline Ave, Boston, MA 02215
179 Grove St, Wellesley, MA 02482
179 Grove St, Wellesley, MA 02482
Phone
(617) 632-3141
(617) 632-2934 (Fax)
(781) 237-7886
(617) 632-2934 (Fax)
(781) 237-7886
Personal information
See more information about DONALD WILLIAM KUFE at radaris.comName
Address
Phone
179 Grove St, Wellesley, MA 02482
179 Grove St, Wellesley, MA 02482
Professional information
Donald William Kufe, Boston MA
Specialties:
Internal Medicine, Medical Oncology, Hematology & Oncology
Work:
Dana-Farber Cancer Institute
450 Brookline Ave, Boston, MA 02215 Dana-Farber Cancer Institute
44 Binney St, Boston, MA 02115
450 Brookline Ave, Boston, MA 02215 Dana-Farber Cancer Institute
44 Binney St, Boston, MA 02115
Education:
University of Rochester(1970)
Phospholipase A2 Inhibitors As Mediators Of Gene Expression
US Patent:
6486170, Nov 26, 2002
Filed:
May 24, 1994
Appl. No.:
08/248058
Inventors:
Dennis E. Hallahan - Des Plaines IL
Ralph R. Weichselbaum - Chicago IL
Donald W. Kufe - Wellesley MA
Ralph R. Weichselbaum - Chicago IL
Donald W. Kufe - Wellesley MA
Assignee:
Arch Development Corporation - Chicago IL
International Classification:
A61K 3144
US Classification:
514297, 4352402, 4351731, 514747, 514263, 514291, 514169
Abstract:
A signaling pathway is identified that involves the activation of phospholipase A2 and protein kinase C in human cells, which in turn confers x-ray induction of the tumor necrosis factor (TNF) gene. Inhibition of phospholipase A2 abolishes radiation-mediated arachidonate production, as well as the subsequent activation of protein kinase C and TNF gene expression. These phospholipase A2 inhibitors may be used to ameliorate the adverse-effects of radiotherapy associated with TNF production.
Gene Transcription And Ionizing Radiation: Methods And Compositions
US Patent:
5770581, Jun 23, 1998
Filed:
Jun 7, 1995
Appl. No.:
8/474445
Inventors:
Ralph R. Weichselbaum - Chicago IL
Dennis E. Hallahan - Park Ridge IL
Vikas P. Sukhatme - Chicago IL
Donald W. Kufe - Wellesley MA
Dennis E. Hallahan - Park Ridge IL
Vikas P. Sukhatme - Chicago IL
Donald W. Kufe - Wellesley MA
Assignee:
Arch Development Corp. - Chicago IL
Dana-Farber Cancer Institute - Boston MA
Dana-Farber Cancer Institute - Boston MA
International Classification:
A61K 4800
US Classification:
514 44
Abstract:
The present invention provides a DNA molecule comprising a radiation responsive enhancer-promoter operatively linked to an encoding region that encodes at least one polypeptide. An encoding region can comprise a single encoding sequence for a polypeptide or two or more encoding sequences encoding DNA binding, activation or repression domains of a transcription factor. Processes for regulating polypeptide expression and inhibiting tumor growth using such DNA molecules are also provided.
Genetically Engineered Polypeptides With Determinants Of The Human Df3 Breast Carcinoma-Associated Antigen
US Patent:
4963484, Oct 16, 1990
Filed:
Jan 29, 1988
Appl. No.:
7/149831
Inventors:
Donald W. Kufe - Wellesley MA
Assignee:
Dana-Farber Cancer Institute, Inc. - MA
International Classification:
C12D 2100, C12N 120, C12N 1500, C07H 1512
US Classification:
435 693
Abstract:
A carbohydrate-free polypeptide coded for by a human DNA sequence of 309 nucleotides is immunologically reactive with monoclonal antibody against the human DF3 breast carcinoma-associated antigen. The nucleotide sequence is also useful as a probe to reveal restriction fragment length polymorphisms in human DNA.
Method Of Inducing Gene Expression By Ionizing Radiation
US Patent:
5571797, Nov 5, 1996
Filed:
May 11, 1994
Appl. No.:
8/241863
Inventors:
Tsuneya Ohno - Boston MA
Ralph R. Weichselbaum - Chicago IL
Donald W. Kufe - Wellesley MA
Ralph R. Weichselbaum - Chicago IL
Donald W. Kufe - Wellesley MA
Assignee:
Arch Development Corporation - Chicago IL
International Classification:
A61K 4800, A61K 5100
US Classification:
514 44
Abstract:
The present invention provides a method for delivering ionizing radiation to specific tissues, resulting in the activation of a DNA molecule comprising a radiation responsive enhancer-promoter operatively linked to an encoding region that encodes at least one polypeptide. The radiation source may be will generally be in the form of a radionuclide, capable of gamma or beta emissions. Processes for regulating polypeptide expression and inhibiting tumor growth using such DNA molecules are also provided.
Methods And Compositions For Viral Enhancement Of Cell Killing
US Patent:
2005014, Jul 7, 2005
Filed:
Sep 21, 2004
Appl. No.:
10/946365
Inventors:
Dennis Hallahan - Park Ridge IL, US
Ralph Weichselbaum - Chicago IL, US
Donald Kufe - Wellesley MA, US
Gregory Sibley - Chapel Hill NC, US
Bernard Roizman - Chicago IL, US
Ralph Weichselbaum - Chicago IL, US
Donald Kufe - Wellesley MA, US
Gregory Sibley - Chapel Hill NC, US
Bernard Roizman - Chicago IL, US
International Classification:
A61K048/00, C12N015/869
US Classification:
424093200, 435456000
Abstract:
The present invention is directed to novel methods of enhancing the effectiveness of DNA damaging agents by exposing cells to viruses prior to or during exposure to the damaging agent. In certain embodiments of the invention, the DNA damaging agent is ionizing radiation, the virus is an adenovirus, and the increase in cell killing is synergistic when compared to radiation alone.
Use Of Df3/Muc1 Regulated Expression In Gene Therapy
US Patent:
7247297, Jul 24, 2007
Filed:
Sep 16, 2002
Appl. No.:
10/244705
Inventors:
Ralph R. Weichselbaum - Chicago IL, US
Donald W. Kufe - Wellesley MA, US
Donald W. Kufe - Wellesley MA, US
Assignee:
The University of Chicago - Chicago IL
Dana-Farber Cancer Institute - Boston MA
Dana-Farber Cancer Institute - Boston MA
International Classification:
A61K 48/00, A01N 63/00
US Classification:
424 932
Abstract:
The present invention provides for improved vectors for use in gene therapy. Utilizing the cancer specific DF3/MUC1 promoter to drive a replication essential gene, vectors are made conditionally replication-competent, permitting wider infection and expression of tumor cells. In addition, therapeutic genes and adjunct therapies further increase anti-tumor efficacy.
Inhibition Of Inflammation Using Antagonists Of Muc1
US Patent:
8614186, Dec 24, 2013
Filed:
May 27, 2010
Appl. No.:
12/789127
Inventors:
Donald W. Kufe - Wellesley MA, US
Surender Kharbanda - Natick MA, US
Surender Kharbanda - Natick MA, US
Assignee:
Dana-Farber Cancer Institute, Inc. - Boston MA
Genus Oncology, LLC. - Chicago IL
Genus Oncology, LLC. - Chicago IL
International Classification:
A61K 38/00, A61P 29/00
US Classification:
514 122
Abstract:
The invention provides for peptides from the MUC1 cytoplasmic domain and methods of use therefor. These peptides can inhibit MUC1 oligomerization, inhibit the interaction of MUC1 with NF-κB or a STAT, and block inflammatory response mediated by NF-κB or STAT signaling.
Muc1 And Abl
US Patent:
2008010, May 8, 2008
Filed:
Jul 27, 2007
Appl. No.:
11/829687
Inventors:
Donald Kufe - Wellesley MA, US
Assignee:
Dana-Farber Cancer Institute, Inc. - Boston MA
International Classification:
A61K 38/00, C12Q 1/48, G06G 7/48, A61K 31/195, A61P 43/00, C12N 5/06, A61K 39/395
US Classification:
424172100, 435015000, 703011000, 435375000, 514002000, 514567000
Abstract:
The present disclosure provides methods of identifying and making compounds and pharmaceutical compositions thereof that inhibit the interaction between MUC1 and Abl. The invention also provides in vivo, in vitro, and ex vivo methods of inhibiting such an interaction. Also featured are in vitro and in vivo methods of stimulating the Abl-dependent apoptotic pathway in cells expressing MUC1. In such methods, the compounds, compositions, and methods described herein are generally useful in the treatment of various cancers. The disclosure also provides methods for inhibiting Abl, and such methods, and compounds and compositions for use in the methods are generally useful for the treatment of cancers, inflammatory conditions, atherosclerotic lesions, and neurologic disorders.
Antagonists Of Muc1
US Patent:
2012004, Feb 23, 2012
Filed:
Feb 14, 2011
Appl. No.:
13/026858
Inventors:
Donald W. Kufe - Wellesley MA, US
Surender Kharbanda - Natick MA, US
Surender Kharbanda - Natick MA, US
International Classification:
A61K 9/127, A61K 38/08, A61K 38/03, A61K 9/14, A61K 9/50, A61P 35/00, A61P 35/02, C12N 5/09, A61K 9/00, B82Y 5/00
US Classification:
424450, 435375, 514 193, 514 11, 424400, 424499, 977906, 977788
Abstract:
The present invention is directed to improved compositions for cellular delivery of peptides. Using segments of only 3-5 positively-charged residues, one can effectively transfer peptides, including therapeutic peptides, into cells. Also provided are modified peptides such as those include stapled and cyclized peptide technology, as well as peptoids/peptidomimetics.